Determination of Higher Order Structure and Hydrogen Deuterium Exchange by LC–MS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Determination of Higher Order Structure and Hydrogen Deuterium Exchange by LC–MS
Hydrogen deuterium exchange by mass spectrometry is a powerful analytical approach that can be used to map higher order structures of proteins.


Pharmaceutical Technology
pp. s38-240

References

1. T.E. Wales et al., Anal. Chem. 80 (17), 6815–6820 (2008).

2. R.E. Iacob, J.P. Murphy, and J.R. Engen, Rapid Commun. Mass Spectrom. 22 (18), 2898–2904 (2008).

3. J. Fang et al., Int. J. Mass Spectrom. 302 (1–3), 19–25 (2011).

4. R.E. Iacob and J.R. Engen, J. Am. Soc. Mass Spectrom. 23 (6), 1003–1010 (2012).

5. W. Hui et al., J. Am. Soc. Mass Spectrom. 23 (3), 498–504 (2012).

6. Z. Zhang and D.L. Smith, Protein Sci. 2 (4), 522–531 (1993).

7. T.E. Wales and J.R. Engen, Mass. Spectrom. Rev. 25 (1), 158–170 (2006).

8. D. Houde et al., Anal. Chem. 81 (7), 5966 (2009).

9. M.J. Chalmers et al., Anal. Chem. 78 (4), 1005–1014 (2006).

10. M.M. Zhu et al., Biochemistry 42 (51), 15388–15397 (2003).

11. Waters Corporation, "Localized Conformation Analysis of Mutated Human IgG1 by HDX–MS and nanoDSC," Application Note 720004224en (2012).

12. A. Baerga-Ortiz et al., Protein Sci. 11 (6), 1300–1308 (2002).

13. D. Houde, S.A. Berkowitz, and J.R. Engen, J. Pharm. Sci. 100 (6), 2071–2086 (2011).

14. J. Ahn, et al., poster at the 9th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry (San Diego, CA, 2012).

15. S. B. Moorthy, S. Badireddy, and G.S. Anand, Int. J. Mass Spectrom. 302 (1–3), 157–166 (2011).

16. H. Xie et al., mAbs 2 (4), 1–16 (2010).

17. J. Ahn et al., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 878 (3–4), 403–408 (2010).

18. G. Pasut and F.M. Veronese, Adv. Drug Deliv. Rev. 61 (13), 1177–1188 (2009).

19. F.M. Veronese and A. Mero, BioDrugs 22 (5), 315–329 (2008).

20. R. B. Greenwald et al., Adv. Drug Deliv. Rev. 55 (22), 217–250 (2003).

21. K.R. Reddy, Ann. Pharmacother. 34 (7–8), 915–923 (2000).

22. S. Kozlowski, Testimony, Subcommittee on Technology and Innovation Committee on Science and Technology, US House of Rep., Sept. 24, 2009.

23. FDA, "FDA Issues Draft Guidance on Biosimilar Product Development," Press Release (Silver Spring, MD, Feb. 9, 2012).

24. L. Heinemann and M. Hompesch, J. of Diabetes Sci. Technol. 5 (3) 741–54 (2011).

25. S. Nakazawa et al., poster at the 60th ASMS Conference on Mass Spectrometry and Allied Topics (Vancouver, BC, 2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here